Free and bound forms of sialic acid in blood plasma of patients with chronic lymphocytic leukemia

  • O. V. Netronina State Institution “Dnіpropetrovsk Medical Academy of the Ministry of Health of Ukraine”
Keywords: glycoconjugate, polychemotherapy, N-acetylneuraminic acid, neuraminidase, sialyltransferase

Abstract

The level of free and bound forms of sialic acids (SА) was investigated in chronic lymphocytic leukemia (CLL) and at different stages of receiving chemotherapy. Determination of sialic acid in blood plasma of patients with CLL before treatment were carried out on the first day and 2 months after taking chemotherapy drugs for combination schemes. Hematologically healthy donors represented the control group. Determination of SA was conducted by thiobarbituric method using trichloroacetic acid for distribution of total sialic acids onto free, protein bound sialic acid, and oligo bound sialic acid. Levelof free sialic acid in serum in chronic lymphocytic leukemia was equal to 43.2% compared to the total number of plasma. On the first day of chemotherapy on background of the general level of oligo bound sialic acids we observed increase in free sialic acid by 24.2% compared to patients not receiving treatment. The level of sialic acids increased 2.6 times compared to norm and featured no significant changes at different stages of treatment. The concentration of sialic acids bound to proteins at 73.4% was lower compared to the control group. After receiving chemotherapy on the first day there was a decline of this indicator to 56.2% compared to groups of patients before treatment. Two months after the treatment the level of all parameters under study returned back to the values obtained at the start of treatment. This data can serve as an additional efficiency criterion of the chemotherapy.

References

Al-Dabagh, M.A., Al-Maya, K.S., 2011. Evalution of immune response in patients with chronic lymphocytic leukemia. Humoral immune response. Iraqi J. Sci. 52(3), 388–393.

Allan, J.M., 2006. The molecular mechanisms of alkylating agent-related acute myeloid leukaemia. Haematologica reports. 2(15), 28–29.

Bose, K.S., Gokhale, P.V., Dwivedi, S., Singh, M., 2013. Quantitative evaluation and correlation of serum glycoconjugates: Protein bound hexoses, sialic acid and fucose in leukoplakia, oral sub mucous fibrosis and oral cancer. J. Nat. Sci. Biol. Med. 4(1), 122–125. >> doi: 10.4103/0976-9668.107275

Büll, C., Boltje, T.J., van Dinther, E.A.W., Peters, T., de Graaf, A.M., Leusen, J.H.W., Kreutz, M., Figdor, C.G., den Brok, M.H., Adema, G.J., 2015. Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. ACS Nano. 9(1), 733–745.

Colovic, N., Bogdsnovic, A., Martinovic-Cemerikic, V., Jankovic, G., 2001. Prognostic significance of serum immunoglobulins in B-chronic lymphocytic leukemia. Archive of Oncology 9(2), 79–82.

Colucci, M., Stöckmann, H., Butera, A., Masotti, A., Baldassarre, A., Giorda, E., Petrini, S., Rudd, P.M., Sitia, R., Emma, F., Vivarelli, M., 2015. Sialylation of N-linked glycans influences the immunomodulatory effects of IgM on T cells. J. Immunol. 194(1), 151–157. >> doi: 10.4049/jimmunol.1402025

Delgado, J., Milligan, D.W., Dreger, P., 2009. Allogenic hematopoietic cell transfusion for chronic lymphocytic leukemia: Ready for prime time. Blood 14(13), 2581–2588.

Fijas', A.T., Frenkel', B.I., 2011. Hronicheskij limfolejkoz: Diagnostika i lechenie [Chronic lymphocytic leukemia: Diagnosis and treatment]. Zhurnal Grodnenskogo Medicinskogo Universiteta 4, 93–97 (in Russian).

Geisler, C.H., van T’ Veer, M.B., Jurlander, J., Walewski, J., Tjønnfjord, G., Itälä Remes, M., Kimby, E., Kozak, T., Polliack, A., Wu, K.L., Wittebol, S., Abrahamse-Testroote, M.C.J., Doorduijn, J., Ghidey Alemayehu, W., van Oers, M.H.J., 2011. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 123(21), 3255–3262. >> doi: 10.1182/blood-2014-01-547737

Gornik, O., Lauc, G., 2008. Glycosylation of serum proteins in inflammatory diseases. Dis. Markers 25(4–5), 267–278. >> doi: 10.1155/2008/493289

Gruszewska, E., Cylwik, B., Panasiuk, A., Szmitkowski, M., Flisiak, R., Chrostek, L., 2014. Total and free serum sialic acid concentration in liver diseases. Bio. Med. Res. Int. ID876096, 1–5. >> doi: 10.1155/2014/876096

Karpishhenko, A.I., 2013. Medicinskie laboratornye tehnologii: Rukovodstvo po klinicheskoj laboratornoj diagnostike [Medical laboratory technology: Guidelines for clinical laboratory diagnostics]. Geotar-Media, Moscow (in Russian).

Maslak, G.S., Kostjuk, O.V., Brazaluk, O.Z., 2013. Syrovatochnyj riven’ sialovyh kyslot ta aktyvnist’ nejraminidazy za umov hronichnogo limfo lejkozu ta na foni himioterapevtychnogo likuvannja [Serum level of sialic acid and neuraminidase activity in chronic lymphocytic leukemia and background chemotherapy]. Vcheni Zapysky Tavrijs’kogo Nacional’nogo Universytetu. Serija Biologija, Himija 26(1), 105–111 (in Ukrainian).

Maslak, G.S., Kostjuk, O.V., Minchenko, D.O., Brazaluk, O.Z., Shevcova, A.I., Minchenko, O.G., 2014. Sial'ovanist' glikoprotei'niv i riven' ekspresii' nejraminidazy NEU1 ta sialiltransferazy ST6GAL1 u limfocytah hvoryh na erytremiju [Glicoprotein sialation and NEU1 and ST6GAL1 expressions in erythremia disease]. Fiziol. Zhurn. 60(5), 14–22 (in Ukrainian).

Nicol, B.M., Prasad, S.B., 2002. Sialic acid changes in Dalton’s lymphoma-bearing mice after cyclophosphamide and cisplatin treatment. Braz. J. Med. Biol. Res. 35(5), 549–553.

Nigam, P.K., Narain, V.S., Kuma, A., 2006. Sialic acid in cardiovascular diseases. Indian. J. Clin. Biochem. 21(1), 54–61. >> doi: 10.1007/BF02913067

Ozkan, O.F., Cıkman, O., Roach, E.C., Kemik, A.S., Gunes, F., Karaayvaz, M., 2014. Effects of acute pancreatitis on plasma total and lipid bound sialic acid levels: An experimental study in rats. Chirurgia 4(109), 486–492.

Patel, P.S., Adhvaryu, S.G., Baxi, B.R., 1991. Tumor markers in leukemia: Evaluation of serum levels of different forms of sialic acid, regan isoenzyme and lactate dehydrogenase. Int. J. Biol. Markers 6(3), 177–182.

Pis'meneckaja, I.J., Batters, T.D., 2013. Izmenenie hromatograficheskih spektrov svobodnyh oligosaharidov plazmy krovi pri sublejkemicheskom mieloze [Chromatographic profile changes of plasma free oligosaccharides in subleukemic myelosis]. Uchenye Zapiski Tavricheskogo Nacіonal'nogo Universiteta im. V.I. Vernadskogo. Serija Biologija, Himija 26(1), 153–160 (in Russian).

Schnaar, R.L., Gerardy-Schahn, R., Hildebrandt, H., 2014. Sialic acids in the brain: Gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol. Rev. 94(2), 461–518. >> doi: 10.1152/physrev.00033.2013

Shade, K.T.C., Anthony, R.M., 2013. Antibody glycosylation and inflammation. Antibodies 2, 392–414. >> doi: 10.3390/antib2030392

Shantaram, M., Rao, A., Rao, A.А., Raja, A., Rao, S., Monteiro, F., 2009. Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann. Indian. Аcad. Neurol. 12(3), 162–166. >> doi: 10.4103/0972-2327.56315

Sladkova, E.A., Skorkina, M.J., 2013. Strukturno-funkcional'nye osobennosti limfocitov bol'nyh limfoblasnym lejkozom [Structural and functional peculiarities of lymphocytes from patients with lymphoblastic leukemia]. Citologija 55(6), 388–393 (in Russian).

Takahashi, K., Raska, M., Stuchlova Horynova, М., Hall, S.D., Poulsen, K., Kilian, M., Hiki, Y., Yuzawa, Y., Moldoveanu, Z., Julian, B.A., Renfrow, M.B., Novak, J., 2014. Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathy. PLoS One 9(11), e113577. >> doi: 10.1371/journal.pone.0099026

Tomaszewska, R., Sonta-Jakimczyk, D., Dyduch, A., Oleynik, I., Mazur, B., 1997. Sialic acid concentration in different stages of malignant lymphoma and leukemia in children. Pediatr. Int. 39(4), 448–450. >> doi: 10.1111/j.1442-200X.1997.tb03615.x

Uslu, C., Taysi, S., Akcay, F., Sutbeyaz, M.Y., Bakan, N., 2003. Serum free and bound sialic acid and alpha-1-acid glycoprotein in patients with laryngeal cancer. Ann. Clin. Lab. Sci. 33(2), 156–159.

Varki, A., 2008. Sialic acids in human health and disease. Trends. Mol. Med. 6, 351–359. >> doi: 10.1016/j.molmed.2008.06.002

Varki, А., Gagneux, Р., 2012. Multifarious roles of sialic acids in immunity. Ann. N.Y. Acad. Sci. 1253, 16–36. >> doi: 10.1111/j.1749-6632.2012.06517.x

Vidarsson, G., Dekkers, G., Rispens, T., 2014. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 5, 520. >> doi: 10.3389/fimmu.2014.00520

Zugmaier, G., Topp, M.S., Alekar, S., Viardot, A., Horst, H.A., Neumann, S., Stelljes, M., Bargou, R.C., Goebeler, M., Wessiepe, D., Degenhard, E., Gökbuget, N., Klinger, M., 2014. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 4, 244. >> doi: 10.1038/bcj.2014.64

Published
2015-08-16
How to Cite
Netronina, O. V. (2015). Free and bound forms of sialic acid in blood plasma of patients with chronic lymphocytic leukemia. Regulatory Mechanisms in Biosystems, 6(2), 108-112. https://doi.org/10.15421/021520